Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Oct 6, 2026: Composition of Faron Pharmaceutical’s Shareho...
Press releases & updates
Composition of Faron Pharmaceutical’s Shareho...
October 6, 2026
Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial
October 1, 2026
Faron Pharmaceuticals Ltd: Convertible bond amortization payment deferred by mutual agreement with HCM
September 30, 2026
Faron Pharmaceuticals Ltd: Convertible bond a...
September 30, 2026
Faron Pharmaceuticals Oy : Announces R&D Day
September 10, 2026
Faron Pharmaceuticals Oy : Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial
August 27, 2026
Faron Pharmaceuticals Ltd: Half-year financia...
August 26, 2026
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
August 3, 2026
Inside Information: Faron announces encouragi...
July 27, 2026
Faron Pharmaceuticals Oy : Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab
July 13, 2026
Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS
June 15, 2026
Faron Pharmaceuticals Ltd: Holding(s) In Company
June 11, 2026
Faron Pharmaceuticals Ltd: Registration of Treasury Shares
June 11, 2026
Faron Pharmaceuticals Receives Decision from ...
June 5, 2026
Faron Pharmaceuticals LTD: Holding(s) in Company
June 1, 2026
Faron Pharmaceuticals LTD: Holding(S) In Company
May 28, 2026
Faron Pharmaceuticals Ltd: Special Rights attached to the First and Second Tranche of Bonds
May 28, 2026
Faron Pharmaceuticals LTD: Holding(s) In Company
May 18, 2026
Faron Pharmaceuticals Oy : AGM Minutes (Faron Pharmaceuticals Minutes AGM 202616946421.2)
May 15, 2026
Faron Pharmaceuticals Ltd: Termination of Liq...
May 6, 2026
Faron Pharmaceuticals Ltd: Directorate Appointment
May 5, 2026
Faron Pharmaceuticals Ltd: Results of the Ann...
May 4, 2026
Faron Pharmaceuticals Ltd: Issuance of warran...
April 30, 2026
Faron Pharmaceuticals Ltd: Remaining offer sh...
April 14, 2026
Notice of Faron Pharmaceuticals LTD's Annual General Meeting
April 10, 2026
Faron publishes final results of its EUR 40.1...
April 9, 2026
Inside Information: Faron publishes prelimina...
April 8, 2026
Suspension - Faron Pharmaceuticals Oy
March 30, 2026
Faron Pharmaceuticals Ltd: Faron appoints new...
March 26, 2026
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMP...
March 11, 2026
Inside Information: Faron publishes the terms...
March 10, 2026
Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026
March 9, 2026
Update to Faron’s Financial Calendar and date...
March 9, 2026
CORRECTION: Faron Pharmaceuticals Ltd's Annual Report 2025 published
March 4, 2026
Correction: Faron Pharmaceuticals Ltd’s Annua...
March 4, 2026
Faron Pharmaceuticals Ltd's Annual Report 2025 Published
March 4, 2026
Faron's Financial Statements Release 1 January to 31 December 2025
March 4, 2026
Faron Pharmaceuticals Ltd’s Annual Report 202...
March 4, 2026
Faron’s Financial Statements Release 1 Januar...
March 4, 2026
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
March 2, 2026
Faron Pharmaceuticals Ltd: Results of the Ext...
March 2, 2026
Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS
March 2, 2026
Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
February 23, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
February 19, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting
February 9, 2026
Faron Pharmaceuticals Ltd: NOTICE TO THE EXTR...
February 9, 2026
Inside Information: Faron Pharmaceuticals Ltd...
February 9, 2026
Faron Pharmaceuticals Ltd: Registration of Ne...
February 3, 2026
Faron Pharmaceuticals Ltd: Approval of Share ...
February 3, 2026
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy
January 29, 2026